Publicacions en col·laboració amb investigadors/es de Universidad del País Vasco/Euskal Herriko Unibertsitatea (110)

2024

  1. Does selective digestive decontamination (SDD) increase antibiotic resistance? Long-term comparison of two intensive care units (with and without SDD) of the same tertiary hospital

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 5, pp. 885-893

  2. Gene therapy with lipid nanoparticles for Fabry disease: Leveraging E-selectin for targeted delivery to endothelial cells

    Journal of Drug Delivery Science and Technology, Vol. 99

  3. Optimizing Antibiotic Therapy for Stenotrophomonas maltophilia Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach

    Antibiotics, Vol. 13, Núm. 6

  4. Population pharmacokinetics of oral fosfomycin calcium in healthy women

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 11, pp. 2837-2845

  5. Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems

    BioDrugs, Vol. 38, Núm. 5, pp. 657-680

  6. Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review

    Drug Delivery and Translational Research, Vol. 14, Núm. 10, pp. 2615-2628

2023

  1. Ceftaroline and Avibactam Removal by Continuous Renal Replacement Therapies: An in vitro Study

    Blood Purification, Vol. 52, Núm. 5, pp. 464-473

  2. Modelo SoTL para evaluar el aprendizaje basado en la investigación en el desarrollo de TFG sobre atención farmacéutica

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  3. Nanopartículas lipídicas funcionalizadas con GalNAc para suplementación génica: aplicación en la enfermedad de Fabry

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  4. Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease

    Pharmaceutics, Vol. 15, Núm. 7

  5. Pharmacokinetic/Pharmacodynamic Analysis of Oral Calcium Fosfomycin: Are Urine Levels Sufficient to Ensure Efficacy for Urinary Tract Infections?

    Pharmaceutics, Vol. 15, Núm. 4

  6. siRNA vectors based on golden lipid nanoparticles for Fabry Disease

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

2022

  1. Community Pharmacy and Primary Health Care - Types of integration

    FIP World Congress of Pharmacy and Pharmaceutical Sciences (80º. Sevilla. 2022)

  2. Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease

    Nanomaterials, Vol. 12, Núm. 14

  3. Oferta de servicios de atención farmacéutica: clave para un nuevo modelo de servicios de salud = Supply of pharmaceutical care services: The key to a new model of health services

    Atención Primaria, Vol. 54, Núm. 1, pp. 102-198

  4. Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

    Journal of Intensive Care, Vol. 10, Núm. 1

  5. mRNA delivery technologies: Toward clinical translation

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 207-293

2021

  1. Evaluation of the adequacy of the antimicrobial therapy of invasive Haemophilus influenzae infections: A pharmacokinetic/pharmacodynamic perspective

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 2, pp. 65-71

  2. Farmazia-zerbitzu profesional asistentzialak Euskal Autonomia Erkidegoko (EAE) farmazietan

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 39, pp. 131-152

  3. Investigación sobre servicios profesionales farmacéuticos asistenciales en el marco de los trabajos fin de grado desarrollados durante las prácticas tuteladas

    Congreso de la Sociedad Española de Farmacia Industrial y Galénica (SEFIG) (15º. Sevilla. 2021)